Stay tuned
FDA snubs AbbVie's prospective Botox heir amid series of manufacturing-related CRLs
The FDA rejected two new products from AbbVie and Grace Therapeutics,
Sanofi gains long-awaited win for tolebrutinib as EU regulator endorses MS drug for approval
After a series of setbacks for Sanofi’s tolebrutinib, the French co
Travere’s launchpad positions Filspari for fast rise toward blockbuster sales: analyst
An established sales force and payer authorization criteria will fuel
Daiichi pushes back annual report, citing reviews amid ‘rapidly changing business conditions’
Daiichi Sankyo has postponed its annual report by two weeks, citing a
Genentech wants ‘All Eyes on DME’ as it taps Damon Wayans for humor-laced campaign
Roche’s Genentech unit is launching a new multimedia campaign aimed
Stay tuned
© 1994 - 2026 B.M. Pharmaceuticals